GlassScriptPhysician profile
Christopher J Mulder
NPI 1356577951
$6,290.03
in general payments reported to CMS, 2019-2025
30 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $1,086 · 2023: $1,536 · 2024: $1,672 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,861 · Education: $33.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.68 |
| Education | $33.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.13 | 2021-2025 | |
| Janssen Biotech, INC. | $946.84 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $670.35 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $480.48 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.20 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $356.45 | 2023-2025 | Omvoh, Zepbound |
| Celgene Corporation | $261.16 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $222.11 | 2024-2025 | Voquezna |
| Pfizer INC. | $167.65 | 2022-2025 | |
| Amgen INC. | $135.16 | 2022-2023 | Avsola, Amjevita |
| Ironwood Pharmaceuticals, INC | $129.45 | 2022-2024 | Linzess |
| Ardelyx, INC. | $121.24 | 2022-2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $99.25 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $96.72 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Lumendi LLC | $92.55 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88.95 | 2022-2024 | Dificid, Zinplava |
| Ipsen Biopharmaceuticals, INC | $83.14 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $77.21 | 2021-2025 | |
| Qol Medical, LLC | $64.69 | 2023-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $57.17 | 2023 | Zeposia |
| Olympus Corporation of The Americas | $48.45 | 2021 | |
| Madrigal Pharmaceuticals | $45.81 | 2025 | Rezdiffra |
| Genzyme Corporation | $39.12 | 2023 | |
| Daiichi Sankyo INC. | $32.40 | 2022 | |
| Braintree Laboratories, INC. | $32.18 | 2023 | Suflave, Sutab |
| Boston Scientific Corporation | $29.97 | 2023 | |
| Intercept Pharmaceuticals, INC. | $29.79 | 2022-2024 | |
| Novo Nordisk INC | $27.27 | 2025 | Wegovy |
| Organon LLC | $25.45 | 2023-2024 | Hadlima |
| Micro-Tech Endoscopy USA, INC. | $11.69 | 2023 | Rapide Balloon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mulder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.